Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.5% and 0.9% ...

13, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva P Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $21.78.

Teva Pharmaceutical reports fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion. Teva reports fourth-quarter adjusted earnings of 71 cents per share, beating ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $30.00. The company’s shares ...

Teva reported earnings before trading began on Wednesday. The positive growth wasn't enough to outweigh guidance for 2025, which disappointed investors. The pharma giant reported sales of $4.2 ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Teva Pharmaceutical Industries Limited before investing. In this article, we go ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...